Amylyx Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio20.17
Forward P/E16.68
P/S Ratio2.952.61110.13
P/B Ratio1.562.297.19
Price/Tangible Book1.562.297.19
Price/FCF93.08
Price/OCF83.39
Enterprise Value Ratios
EV/Revenue0.291.69103.12
EV/EBITDA16.13
EV/EBIT16.59
EV/FCF60.27
Profitability & Returns
Return on Equity (ROE)-1.01%0.13%-0.93%-1.88%
Return on Assets (ROA)-0.51%0.05%-0.51%-0.86%-2.81%
Return on Invested Capital (ROIC)-10.32%1.06%
Return on Capital Employed (ROCE)-1.77%0.09%-0.58%-0.94%-5.75%
Leverage & Solvency Ratios
Debt/Equity0.010.010.020.27
Debt/EBITDA0.10
Debt/FCF0.40
Liquidity Ratios
Current Ratio6.675.668.206.031.86
Quick Ratio6.235.027.785.531.76
Efficiency Ratios
Asset Turnover0.250.840.090.010.07
Inventory Turnover6.39
Yield & Distribution Ratios
Earnings Yield-1.17%0.05%-0.08%
FCF Yield-0.79%0.01%-0.07%
Buyback Yield0.03%-0.20%-7.88%-0.08%-0.03%